WO2023062354A3 - Nanoparticulate formulation - Google Patents
Nanoparticulate formulation Download PDFInfo
- Publication number
- WO2023062354A3 WO2023062354A3 PCT/GB2022/052570 GB2022052570W WO2023062354A3 WO 2023062354 A3 WO2023062354 A3 WO 2023062354A3 GB 2022052570 W GB2022052570 W GB 2022052570W WO 2023062354 A3 WO2023062354 A3 WO 2023062354A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nanoparticles
- nanoparticulate formulation
- medical treatment
- nanoparticulate compositions
- nanoparticulate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present disclosure relates to nanoparticles and nanoparticulate compositions; methods of preparing such nanoparticles and nanoparticulate compositions; and associated methods of medical treatment and uses of such nanoparticles and nanoparticulate compositions for medical treatment, including the use of such nanoparticles for the manufacture of medicaments for medical treatment.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163254253P | 2021-10-11 | 2021-10-11 | |
US63/254,253 | 2021-10-11 | ||
GB2201351.0 | 2022-02-02 | ||
GBGB2201351.0A GB202201351D0 (en) | 2022-02-02 | 2022-02-02 | Nanoparticulate formulation |
US202263321886P | 2022-03-21 | 2022-03-21 | |
US63/321,886 | 2022-03-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023062354A2 WO2023062354A2 (en) | 2023-04-20 |
WO2023062354A3 true WO2023062354A3 (en) | 2023-06-01 |
Family
ID=80621217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2022/052570 WO2023062354A2 (en) | 2021-10-11 | 2022-10-11 | Nanoparticulate formulation |
Country Status (3)
Country | Link |
---|---|
CA (1) | CA3179062A1 (en) |
GB (1) | GB202201351D0 (en) |
WO (1) | WO2023062354A2 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0899897A (en) * | 1994-08-05 | 1996-04-16 | Shionogi & Co Ltd | Interleukin 2 absorbing type lipid globule |
WO2013155487A1 (en) * | 2012-04-12 | 2013-10-17 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
US20160331743A1 (en) * | 2014-01-10 | 2016-11-17 | Urogen Pharma Ltd | Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder |
US20180296850A1 (en) * | 2017-04-14 | 2018-10-18 | Tianxin Wang | Reagents and methods for cancer treatment using Magnetic particle |
WO2020220000A1 (en) * | 2019-04-25 | 2020-10-29 | Tlc Biopharmaceuticals, Inc. | Liposomal sustained-release compositions containing a therapeutic drug and use thereof |
-
2022
- 2022-02-02 GB GBGB2201351.0A patent/GB202201351D0/en not_active Ceased
- 2022-10-11 CA CA3179062A patent/CA3179062A1/en active Pending
- 2022-10-11 WO PCT/GB2022/052570 patent/WO2023062354A2/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0899897A (en) * | 1994-08-05 | 1996-04-16 | Shionogi & Co Ltd | Interleukin 2 absorbing type lipid globule |
WO2013155487A1 (en) * | 2012-04-12 | 2013-10-17 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
US20160331743A1 (en) * | 2014-01-10 | 2016-11-17 | Urogen Pharma Ltd | Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder |
US20180296850A1 (en) * | 2017-04-14 | 2018-10-18 | Tianxin Wang | Reagents and methods for cancer treatment using Magnetic particle |
WO2020220000A1 (en) * | 2019-04-25 | 2020-10-29 | Tlc Biopharmaceuticals, Inc. | Liposomal sustained-release compositions containing a therapeutic drug and use thereof |
Non-Patent Citations (1)
Title |
---|
OU WENQUAN ET AL: "Regulatory T Cells Tailored with pH-Responsive Liposomes Shape an Immuno-Antitumor Milieu against Tumors", APPLIED MATERIALS & INTERFACES, vol. 11, no. 40, 9 October 2019 (2019-10-09), US, pages 36333 - 36346, XP055963893, ISSN: 1944-8244, DOI: 10.1021/acsami.9b11371 * |
Also Published As
Publication number | Publication date |
---|---|
WO2023062354A2 (en) | 2023-04-20 |
CA3179062A1 (en) | 2023-04-11 |
GB202201351D0 (en) | 2022-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014264224B2 (en) | Doped metal oxide nanoparticles of and uses thereof | |
WO2018077944A3 (en) | 4,5-annulated 1,2,4-triazolones | |
PH12016500389B1 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
NZ722927A (en) | Aerosol pirfenidone and pyridone analog compounds and uses thereof | |
EP4241772A3 (en) | Process for the preparation of compounds useful for treating spinal muscular atrophy | |
MX2020001403A (en) | Quinoline derivatives for treating infections with helminths. | |
MX2019003397A (en) | Methods of treating mitochondrial and metabolic disorders. | |
GEP201706780B (en) | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
GB0814302D0 (en) | Compounds and methods | |
TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
MY163235A (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
EA201291089A1 (en) | METHOD FOR OBTAINING PHARMACEUTICAL PREPARATIONS INTENDED FOR ORAL ADMINISTRATION, CONTAINING ONE OR MORE ACTIVE INGREDIENTS AND CONTAINING COMPOSITIONS | |
WO2017128917A8 (en) | Parazole condensed-ring derivatives and preparation method thereof and application thereof in treatment of cancers, inflammation and immune diseases | |
MX2020011873A (en) | New quinoline derivatives. | |
EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
MX2021005745A (en) | Plant tissue-derived nanoparticles and food powders. | |
WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
WO2011009714A3 (en) | Benzoquinolizinium salt derivatives as anticancer agents | |
MX2012001529A (en) | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators. | |
WO2021046315A3 (en) | Inhibitors of encephalitic alphaviruses | |
WO2016040814A3 (en) | Disulfide polymers and methods of use | |
WO2010080754A3 (en) | Nanoparticle pharmaceutical formulations | |
WO2009084041A3 (en) | Pharmaceutical compositions of dexibuprofen | |
WO2023062354A3 (en) | Nanoparticulate formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22790012 Country of ref document: EP Kind code of ref document: A2 |